Cerevel Therapeutics Holdings Inc (DELISTED) (CERE:DL)
44.96
0.00 (0.00%)
USD |
NASDAQ |
Aug 01, 16:00
Cerevel Therapeutics Holdings Shareholders Equity (Quarterly): 564.46M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 564.46M |
| December 31, 2023 | 673.74M |
| September 30, 2023 | 272.96M |
| June 30, 2023 | 350.50M |
| March 31, 2023 | 431.71M |
| December 31, 2022 | 521.24M |
| September 30, 2022 | 603.36M |
| June 30, 2022 | 452.81M |
| Date | Value |
|---|---|
| March 31, 2022 | 521.50M |
| December 31, 2021 | 578.73M |
| September 30, 2021 | 629.08M |
| June 30, 2021 | 293.89M |
| March 31, 2021 | 340.04M |
| December 31, 2020 | 384.52M |
| September 30, 2020 | 142.59M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
142.59M
Minimum
Sep 2020
673.74M
Maximum
Dec 2023
450.74M
Average
452.81M
Median
Jun 2022
Shareholders Equity (Quarterly) Benchmarks
| AbbVie Inc | 6.032B |
| Amgen Inc | 7.527B |
| Biogen Inc | 16.36B |
| Gilead Sciences Inc | 18.39B |
| Eli Lilly and Co | 14.24B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.127B |
| Total Liabilities (Quarterly) | 562.89M |